Hot-topic debate on tolerance: Immunosuppression withdrawal

Liver Transplantation

Volumn 17, Issue SUPPL. 3, 2011, Pages

  Sánchez Fueyo, Alberto ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; BIOLOGICAL MARKER;

ACUTE GRAFT REJECTION; ARTICLE; DRUG EFFICACY; DRUG WITHDRAWAL; GRAFT RECIPIENT; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER TRANSPLANTATION; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; DRUG EFFECT; GRAFT REJECTION; IMMUNOLOGY; METABOLISM; MORBIDITY; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

BIOLOGICAL MARKERS; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MORBIDITY; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 84857178649     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22421     Document Type: Article

References (31)

1. Dantal J, Soulillou JP. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl JMed 2005;352: 1371-1373.
2. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351: 2715-2729.
3. Gelson W, Hoare M, Dawwas MF, Vowler S, Gibbs P, Alexander G. The pattern of late mortality in liver transplant recipients in the United Kingdom. Transplantation 2011;91: 1240-1244.
4. Lerut J, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am J Transplant 2006;6: 1774-1780.
5. Starzl TE. Cell migration and chimerism-a unifying concept in transplantation-with particular reference to HLA matching and tolerance induction. Transplant Proc 1993;25(pt 1): 8-12.
6. Mazariegos GV, Reyes J, Marino IR, Demetris AJ, Flynn B, Irish W, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997;63: 243-249.
7. Devlin J, Doherty D, Thomson L, Wong T, Donaldson P, Portmann B, Williams R. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 1998;27: 926-933.
8. Girlanda R, Rela M, Williams R, O'Grady JG, Heaton ND. Long-term outcome of immunosuppression withdrawal after liver transplantation. Transplant Proc 2005;37: 1708-1709.
9. Takatsuki M, Uemoto S, Inomata Y, Sakamoto S, Hayashi M, Ueda M, et al. Analysis of alloreactivity and intragraft cytokine profiles in living donor liver transplant recipients with graft acceptance. Transpl Immunol 2001; 8: 279-286.
10. Eason JD, Cohen AJ, Nair S, Alcantera T, Loss GE. Tolerance: is it worth the risk? Transplantation 2005;79: 1157-1159.
11. Tryphonopoulos P, Tzakis AG, Weppler D, Garcia- Morales R, Kato T, Madariaga JR, et al. The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am J Transplant 2005;5: 608-613.
12. Tisone G, Orlando G, Cardillo A, Palmieri G, Manzia TM, Baiocchi L, et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 2006;44: 702-709.
13. Assy N, Adams PC, Myers P, Simon V, Minuk GY, Wall W, Ghent CN. Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid. Transplantation 2007;83: 1571-1576.
14. Pons JA, Revilla-Nuin B, Baroja-Mazo A, Ramírez P, Martínez-Alarcón L, Sánchez-Bueno F, et al. FoxP3 in peripheral blood is associated with operational tolerance in liver transplant patients during immunosuppression withdrawal. Transplantation 2008;86: 1370-1378.
15. Feng S, Ekong U, Lobritto S, Demetris A, Rosenthal P, Alonso E, Tchao N. ITN029ST: immunosuppression withdrawal in pediatric recipients of parental living donor liver transplants: preliminary results of a pilot study [abstract]. Am J Transplant 2009;9(suppl 2): 244.
16. Benitez CE, Lozano JJ, Martinez-Llordella M, Puig-Pey I, Lopez M, Tisone G, et al. Use of transcriptional biomarkers to identify liver transplant recipients who can successfully discontinue immunosuppressive therapy [abstract]. Am J Transplant 2010;10(suppl 4): 191.
17. Yoshitomi M, Koshiba T, Haga H, Li Y, Zhao X, Cheng D, et al. Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation. Transplantation 2009;87: 606-614.
18. Bühler LH, Spitzer TR, Sykes M, Sachs DH, Delmonico FL, Tolkoff-Rubin N, et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 2002;74: 1405-1409.
19. Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008;358: 353-361.
20. Donckier V, Troisi R, Le Moine A, Toungouz M, Ricciardi S, Colle I, et al. Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion. Liver Transpl 2006;12: 1523-1528.
21. Donckier V, Craciun L, Lucidi V, Buggenhout A, Troisi R, Rogiers X, et al. Acute liver transplant rejection upon immunosuppression withdrawal in a tolerance induction trial: potential role of IFN-gamma-secreting CD8+ T cells. Transplantation 2009;87(suppl): S91-S95.
22. Calne R, Friend P, Moffatt S, Bradley A, Hale G, Firth J, et al. Prope tolerance, perioperative Campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998;351: 1701-1702.
23. Starzl TE, Murase N, Abu-Elmagd K, Gray EA, Shapiro R, Eghtesad B, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003;361: 1502-1510.
24. Marcos A, Eghtesad B, Fung JJ, Fontes P, Patel K, Devera M, et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 2004;78: 966-971.
25. De Ruvo N, Cucchetti A, Lauro A, Masetti M, Cautero N, Di Benedetto F, et al. Preliminary results of a ''prope'' tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation. Transplantation 2005;80: 8-12.
26. Benítez CE, Puig-Pey I, López M, Martínez-Llordella M, Lozano JJ, Bohne F, et al. ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. Am J Transplant 2010;10: 2296-2304.
27. Martínez-Llordella M, Lozano JJ, Puig-Pey I, Orlando G, Tisone G, Lerut J, et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008;118: 2845-2857.
28. Martínez-Llordella M, Puig-Pey I, Orlando G, Ramoni M, Tisone G, Rimola A, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007;7: 309-319.
29. Li Y, Koshiba T, Yoshizawa A, Yonekawa Y, Masuda K, Ito A, et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 2004;4: 2118-2125.
30. Mazariegos GV, Zahorchak AF, Reyes J, Chapman H, Zeevi A, Thomson AW. Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. Am J Transplant 2005;5: 314-322.
31. Li Y, Zhao X, Cheng D, Haga H, Tsuruyama T, Wood K, et al. The presence of Foxp3 expressing T cells within grafts of tolerant human liver transplant recipients. Transplantation 2008;86: 1837-1843.